Gemcitabine combined with nedaplatin for elderly patients with advanced non-small cell lung cancer

Abstract

Listen

Translate article

Objective To explore the efficacy and toxic reaction of gemcitabine ( GEM ) combined with nedaplatin ( NDP )in the treatment of elder patients with advanced non-small cell lung cancer ( NSCLC ).Methods 70 patients with advanced NSCLC comfirmed by pathology or cytology who had been treated from June 2009 to June 2011 were included in this study.The patients were randomly assigned to receive GEM plus either NDP ( 35 patients,study group ),or DDP ( 35 patients,control group ).The efficacy was assessed after two cycles of treatment.Results The total effectiveness rate,median survival duration,and one-year survival rate did not differ significantly between the study group and the control group( 40.0％ vs.42.8％,8.7 months vs.9.2 months,and 33.5％ vs.32.7％ P＞ 0.05 ).The incidence rates of leukopenia,decreased haemoglobin level,and thrombocytopenia were 54.3％,34.2％,and 57％in the control group and 57％,42.8％,and 62.9％ in the study group,respectively.There was no statistical significance ( P ＞ 0.05 ).The incidence rate of gastrointestinal reactions was significantly lower in the study group than in the control group( P＜ 0.05 ).The rate of liver and kidney function damage was lower,with no significant difference between the two groups ( P＞ 0.05 ).Conclusions Platin-based chemotherapy is efficacious in the treatment of advanced NSCLC.GEM combined NDP has a similar efficacy with GEM plus DDP.NDP has lower gastrointestinal reaction,lower hepatorenal toxicity,and higher tolerance and compliance in patients. Key words: Gemcitabine; Nedaplatin; Cisplatin; Non-small cell lung cancer; Chemotherapy